

MOR106: Anti-IL-17C for Atopic Dermatitis

The MorphoSys-Galapagos Collaboration




&




- MOR106 arises from a strategic discovery and co-development alliance between MorphoSys and Galapagos
- Galapagos provides the disease-related biology including cellular assays and targets discovered using its target discovery platform
- MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target and contributes full CMC development of this compound
- MorphoSys and Galapagos co-develop MOR106 50/50

MOR106 is Effective in Two Animal Models Relevant for Atopic Dermatitis

FLAKY TAIL MOUSE MODEL



CALCIPOTRIOL INDUCED ATOPIC DERMATITIS ON MURINE EAR SKIN



Skin severity score: composite score of erythema, excoriation & scaling

Psoriasis and Atopic Dermatitis

Approved Antibody Therapies

Psoriasis



Atopic Dermatitis



Market Forecast

Double from 2015-2025 to \$16 bn (7MM)

Double from 2014-2024 to \$7.3 bn (7MM)

Mod-severe Population

3 m

9-17 m

Current Antibody Therapies

anti-TNF α

- Cimzia[®] (certolizumab pegol)
- Enbrel[®] (etanercept)
- Humira[®] (adalimumab)
- Remicade[®] (infliximab)
- Simponi[®] (golimumab)

anti-IL-17A or anti-IL-17RA

- Cosentyx[®] (secukinumab)
- Siliq[®] (brodalumab)
- Taltz[®] (ixekizumab)

anti-IL-12/23 or anti-IL-23

- Stelara[®] (ustekinumab)
- Tremfya[™] (guselkumab)

anti-IL-4R

- Dupixent[®] (dupilumab)

Data based on Artisan Healthcare Analysis, January 2017

MOR106 Phase 1 Studies in Atopic Dermatitis



ATOPIC DERMATITIS:

Inflammatory skin disease characterized by red, dry skin causing severe itch (35M patients in US, Europe and Japan)

Single ascending dose	Healthy males, 7 cohorts, i.v. infusion (n=42)	7-week follow up
	Placebo (n=14)	
4 WEEKS		
Multiple ascending dose	Patients, 3 cohorts, weekly i.v. infusion (n=18)	10-week follow up
	Placebo (n=6)	

- Primary & secondary objectives: safety/tolerability & pharmacokinetics
- Exploratory objectives:
Eczema Area & Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), Investigator Global Assessment (IGA), serum TARC (CCL17)
- Topline results expected shortly